newsfilter
← Latest News
PR Newswire·

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad™ Single registration study with pre-agreed upon endpoints planned to